Table 2.

Median treatment duration and proportion of patients remaining on treatment

Indication	Median treatment duration (month)	Patients remaining on treatment
		Baseline (%)	After 0.5 year (%)	After 1.5 years (%)	After 2.5 years (%)	After 3.5 years (%)	After 4.5 years (%)
Non-small-cell-lung cancer [80]	4.9	100	43	8	1	0	0
Metastatic renal cell carcinoma [4]	9.7	100	65	27	12	5	2
Recurrent glioblastoma [5]	4.1a	100	37	5	1	0	0
Cervical cancer [81]	4.8b	100	42	8	1	0	0
Metastatic colorectal cancer [8, 9, 82]	4.6c	100	40	7	1	0	0

^aEstimated based on observed duration of three 6-week treatment cycles

^bEstimated based on observed duration of seven 21-day treatment cycles

^cEstimated based on observed duration of ten 14-day treatment cycles and was applied to estimate the proportion of patients remaining on treatment